BR112017012487A2 - composição aquosa - Google Patents
composição aquosaInfo
- Publication number
- BR112017012487A2 BR112017012487A2 BR112017012487A BR112017012487A BR112017012487A2 BR 112017012487 A2 BR112017012487 A2 BR 112017012487A2 BR 112017012487 A BR112017012487 A BR 112017012487A BR 112017012487 A BR112017012487 A BR 112017012487A BR 112017012487 A2 BR112017012487 A2 BR 112017012487A2
- Authority
- BR
- Brazil
- Prior art keywords
- aqueous composition
- salt
- compound
- brimonidine
- solvate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014251708 | 2014-12-12 | ||
PCT/JP2015/084802 WO2016093344A1 (ja) | 2014-12-12 | 2015-12-11 | 新規水性組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017012487A2 true BR112017012487A2 (pt) | 2017-12-26 |
Family
ID=56107521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017012487A BR112017012487A2 (pt) | 2014-12-12 | 2015-12-11 | composição aquosa |
Country Status (11)
Country | Link |
---|---|
US (1) | US10220043B2 (pt) |
EP (1) | EP3231429B1 (pt) |
JP (2) | JP5951920B1 (pt) |
KR (1) | KR102502053B1 (pt) |
CN (1) | CN107106571B (pt) |
BR (1) | BR112017012487A2 (pt) |
CA (1) | CA2970263A1 (pt) |
MX (1) | MX2017007573A (pt) |
MY (1) | MY178881A (pt) |
SG (1) | SG11201704737SA (pt) |
WO (1) | WO2016093344A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101846804B1 (ko) * | 2014-09-25 | 2018-04-06 | 코와 가부시키가이샤 | 리파수딜 함유 수성 조성물을 위한 의약 제제 |
TWI699205B (zh) * | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | 用於預防或治療青光眼之藥物療法 |
CA3086445A1 (en) * | 2017-12-21 | 2019-06-27 | Santen Pharmaceutical Co., Ltd. | Omidenepag combination |
WO2019235456A1 (ja) * | 2018-06-05 | 2019-12-12 | 千寿製薬株式会社 | 水性液剤 |
JP2020033290A (ja) * | 2018-08-29 | 2020-03-05 | 興和株式会社 | 水性組成物 |
CN109734701B (zh) * | 2019-03-04 | 2020-07-14 | 中国药科大学 | Rock抑制剂-二氯乙酸复盐及其制备方法和用途 |
CN111518028A (zh) * | 2020-05-12 | 2020-08-11 | 中国药科大学 | 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途 |
CN116159018A (zh) * | 2023-03-01 | 2023-05-26 | 中国药科大学 | 一种新型外用溴莫尼定凝胶剂 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4212149B2 (ja) | 1998-06-11 | 2009-01-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | 医薬 |
EP1726306B1 (en) | 2004-03-16 | 2013-10-30 | Asahi Kasei Pharma Corporation | Fasudil-containing preparation and method of improving stability thereof |
US20060142270A1 (en) * | 2004-12-23 | 2006-06-29 | Kowa Co., Ltd. | Preventing or treating agent for glaucoma |
TWI367098B (en) | 2004-12-23 | 2012-07-01 | Kowa Co | Treating agent for glaucoma |
WO2006115244A1 (ja) | 2005-04-25 | 2006-11-02 | D. Western Therapeutics Institute, Inc. | 4-ブロモイソキノリン誘導体及びこれを含有する医薬 |
KR101326425B1 (ko) * | 2005-06-21 | 2013-11-11 | 코와 가부시키가이샤 | 녹내장의 예방 또는 치료제 |
JP4800720B2 (ja) | 2005-09-21 | 2011-10-26 | 興和株式会社 | 点眼用組成物 |
JP2012250953A (ja) * | 2011-06-06 | 2012-12-20 | Santen Pharmaceut Co Ltd | アデノシン誘導体とα2受容体作動薬の組合せ剤 |
JP2013035802A (ja) * | 2011-08-10 | 2013-02-21 | D Western Therapeutics Institute Inc | 緑内障又は高眼圧症の予防又は治療剤 |
TWI699205B (zh) | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | 用於預防或治療青光眼之藥物療法 |
-
2015
- 2015-12-11 MX MX2017007573A patent/MX2017007573A/es active IP Right Grant
- 2015-12-11 CN CN201580067654.9A patent/CN107106571B/zh active Active
- 2015-12-11 BR BR112017012487A patent/BR112017012487A2/pt not_active IP Right Cessation
- 2015-12-11 CA CA2970263A patent/CA2970263A1/en not_active Abandoned
- 2015-12-11 JP JP2016514774A patent/JP5951920B1/ja active Active
- 2015-12-11 WO PCT/JP2015/084802 patent/WO2016093344A1/ja active Application Filing
- 2015-12-11 EP EP15867038.0A patent/EP3231429B1/en active Active
- 2015-12-11 MY MYPI2017702093A patent/MY178881A/en unknown
- 2015-12-11 KR KR1020177015679A patent/KR102502053B1/ko active IP Right Grant
- 2015-12-11 SG SG11201704737SA patent/SG11201704737SA/en unknown
- 2015-12-11 US US15/534,069 patent/US10220043B2/en not_active Expired - Fee Related
-
2016
- 2016-06-06 JP JP2016112567A patent/JP2016155870A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170360799A1 (en) | 2017-12-21 |
JP5951920B1 (ja) | 2016-07-13 |
US10220043B2 (en) | 2019-03-05 |
SG11201704737SA (en) | 2017-07-28 |
EP3231429B1 (en) | 2021-03-17 |
WO2016093344A1 (ja) | 2016-06-16 |
EP3231429A4 (en) | 2018-08-08 |
KR20170095847A (ko) | 2017-08-23 |
CA2970263A1 (en) | 2016-06-16 |
KR102502053B1 (ko) | 2023-02-20 |
CN107106571B (zh) | 2021-02-05 |
JP2016155870A (ja) | 2016-09-01 |
JPWO2016093344A1 (ja) | 2017-04-27 |
CN107106571A (zh) | 2017-08-29 |
MX2017007573A (es) | 2018-01-17 |
EP3231429A1 (en) | 2017-10-18 |
MY178881A (en) | 2020-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017012487A2 (pt) | composição aquosa | |
BR112017012491A2 (pt) | composição | |
BR112017006148A2 (pt) | produto farmacêutico | |
BR112017012483A2 (pt) | composição aquosa | |
PH12016500169A1 (en) | Polymorph of syk inhibitors | |
BR112017002827A2 (pt) | derivado de quinolina altamente puro e método para produção do mesmo | |
AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
BR112017006253A2 (pt) | novos compostos | |
BR112017006149A2 (pt) | preparação farmacêutica | |
BR112015018188A2 (pt) | composição e método para o controle de pestes | |
BR112017003898A2 (pt) | análogos de dioxolano de uridina para o tratamento de câncer | |
BR112017011316A2 (pt) | derivados heterocíclicos e uso destes | |
BR112017004925A2 (pt) | composição e método | |
BR112015024075A2 (pt) | compostos de piridinilpirazoloquinolina | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
BR112016021428A2 (pt) | método para produção de metaloaluminofosfatos com troca de metais pela troca iônica no estado sólido em baixas temperaturas | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
MX2017003941A (es) | Composicion acuosa. | |
CY1120402T1 (el) | Νεο αλας ιμβαμπραδινης και μεθοδος παρασκευης αυτου | |
EA201650042A1 (ru) | Соль цинка или меди(ii) и ее применение в качестве биоцида | |
TH170794B (th) | เกลือของอนุพันธ์เซฟาโลสปอริน, ของแข็งคริสตัลไลน์ของมัน และวิธีของการผลิตของมัน | |
TH168624B (th) | อนุพันธ์กลูโคไพแรโนซิล-ซับสทิทิวเทด อินโดล-ยูเรีย และการใช้สารเหล่านั้น เป็นตัวยับยั้ง sglt | |
PL407842A1 (pl) | Sole amoniowe o czynności herbicydowej | |
AR103070A1 (es) | Derivados de 5-clorobenzo[d]isoxazol | |
TW201613928A (en) | Vinyl compounds as inhibitors for FGFR and VEGFR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |